| Ytd | 32.16% | |
| 1y | -40.82% |
| Open | 10.14 | Prev Close | 10.13 | Low | 10.14 | High | 10.17 | Mkt Cap | 448.68M |
| Vol | 0.00 | Avg Vol | 1.34M | EPS | -4.73 | P/E | -2.15 | Forward P/E | -1.26 |
| Beta | 1.31 | Short Ratio | 3.66 | Inst. Own | 103.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 10.13 | 200-d Avg | 8.29 | 1yr Est | 25.00 |
ITOS News
NEW YORK , Aug. 20, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investiga
NEW YORK and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Cha
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is invest
NEW YORK , July 21, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law v
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc.
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab
- Board of Directors intends to cease operations - Company to focus efforts on selecting best path t
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in prog
The consensus price target hints at a 211.1% upside potential for iTeos Therapeutics (ITOS). While e
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim da
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc.
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim da
iTeos' lead molecule, Belrestotug, shows promising efficacy in trials despite setbacks in the anti-T
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab
iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cance
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall respons
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc.
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday a
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report
On Wednesday morning, 198 companies hit new 52-week highs.
Friday's session saw 466 companies set new 52-week highs.